Clinical Trials
8
Active:4
Completed:3
Trial Phases
3 Phases
Phase 1:4
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (50.0%)Phase 2
2 (25.0%)Phase 3
2 (25.0%)Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- InCarda Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05039359
- Locations
- 🇺🇸
UC Davis Medical Center, Davis, California, United States
🇺🇸Memorial Care, Long Beach, California, United States
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- InCarda Therapeutics, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03539302
- Locations
- 🇧🇪
Imelda, Bonheiden, Belgium
🇳🇱OLVG, Amsterdam, Netherlands
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
News
No news found